Vesugen is short synthetic peptide marketed as a vascular bioregulator. Researchers examine it in relation to vascular endothelium and vessel-ageing models.

Researchers study whether it can influence the cells lining blood vessels and age-related vessel changes. Strong independent clinical evidence is lacking.

Proposed to influence tissue-specific gene expression; a validated receptor-level mechanism is not established.

Evidence is limited, regional and largely preclinical; exact sequence and source documentation are essential.

No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.